Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics, Inc. (ALDX) announced that its CEO will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The virtual conference will take place on February 13-14, 2024. The conversation will be available for live webcast and archived for 90 days.
02/06/2024 - 07:00 AM
LEXINGTON, Mass. --(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The conference will be held virtually on February 13-14, 2024.
Dr. Brady’s conversation with Justin Kim, Senior Research Analyst at Oppenheimer & Co., is scheduled to begin at 4:30 p.m. ET Tuesday, February 13, 2024. To listen to the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com . Following the fireside chat, the webcast will be archived for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of proliferative vitreoretinopathy and retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206438268/en/
Investor & Media:
David Burke
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
When will the Oppenheimer 34th Annual Healthcare Life Sciences Conference take place?
The conference will be held on February 13-14, 2024.
Who will participate in the fireside chat at the conference?
Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra Therapeutics, Inc.
Where can the live webcast of the conversation be accessed?
The live webcast can be accessed in the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com.
For how long will the webcast be archived?
The webcast will be archived for 90 days after the fireside chat.
ALDX Rankings
#5198 Ranked by Stock Gains
ALDX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About ALDX
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
